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Vascular endothelial growth factor (VEGF) is an intensively studied molecule that has significant potential, both in stimulating
angiogenesis and as a target for antiangiogenic approaches. We utilised MCF-7 breast cancer cells transfected with either of two of
the major VEGF isoforms, VEGF121 or VEGF165, or fibroblast growth factor-1 (FGF-1) to distinguish the effects of these factors on
tumour growth, vascular function, and oxygen delivery. While each transfectant demonstrated substantially increased tumorigenicity
and growth rate compared to vector controls, only VEGF121 produced a combination of significantly reduced total and perfused
vessel spacing, as well as a corresponding reduction in overall tumour hypoxia. Such pathophysiological effects are of potential
importance, since antiangiogenic agents designed to block VEGF isoforms could in turn result in the development of therapeutically
unfavourable environments. If antiangiogenic agents are also combined with conventional therapies such as irradiation or
chemotherapy, microregional deficiencies in oxygenation could play a key role in ultimate therapeutic success.
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Vascular endothelial growth factor (VEGF), perhaps the
most critical regulator of angiogenesis in both tumours and
normal tissue, is regulated by numerous factors, most notably
tissue oxygen level (Shweiki et al, 1992). Vascular endothelial
growth factor exists as six alternatively spliced isoforms,
predominantly VEGF121 and VEGF165 (Ferrara, 1999), and a
number of previous workers have studied vascular changes in
tumour lines transfected to overexpress specific isoforms.
An almost universal finding among all of the different isoforms
has been that overexpression enhances tumorigenesis and tumour
progression (Bicknell, 1997). In MCF-7 human breast carcinomas
specifically, which normally produce low levels of VEGF, VEGF121
transfectants formed faster growing, more vascularised tumours
in comparison to wild type (Zhang et al, 1995). In vitro and in vivo,
VEGF121-transfected MCF-7 tumour cells were shown to be
much more tumorigenic and angiogenic than VEGF165, perhaps
due to the enhanced ability of the VEGF121 isoform to freely diffuse
from the cells producing it (Zhang et al, 2000). Our previous
studies have also shown that overexpression of VEGF121
or VEGF165 by oestrogen-dependent MCF-7 breast cells stimulates
breast tumour formation and neovascularisation in an oestrogen-
independent fashion in ovariectomised mice, in the absence
of 17 b-estradiol treatment (Guo et al, 2003). These findings
suggested that upregulation of VEGF in oestrogen-dependent
breast cancer contributes to the acquisition of oestrogen-
independent cancer growth by stimulating tumour angio-
genesis and progression through both autocrine and paracrine
mechanisms.
Findings in other tumour cell lines have been somewhat mixed.
Using transformed murine fibrosarcoma cells (that initially lack
VEGF) to specifically express each of the isoforms, it was found
that only VEGF164 (the murine version of VEGF165) could fully
rescue tumour growth (Grunstein et al, 2000). In this study,
vascular densities were unchanged in either the VEGF120 or
VEGF165 transfectants compared to vector controls. In the
WM1341B melanoma cell line, however, VEGF165 produced much
more richly vascularised tumours in transfectants, despite the fact
that VEGF121 was the predominant isoform in parental cell lines
(Yu et al, 2002). In gliomas, different VEGF isoforms demonstrated
different biological activities than each other at the same site, as
well as different activities for the same isoform when implanted at
different sites (Guo et al, 2001).
Although the effects of VEGF121 and VEGF165 have been studied
in a range of tumour models, techniques have not been available
for quantifying the corresponding alterations in tumour blood
flow and oxygenation until fairly recently. Since several promising
antiangiogenic strategies rely on blocking either VEGF or its
receptors (Gerber et al, 2000; Bruns et al, 2002), such accompany-
ing pathophysiological changes are clearly of interest. Reductions
or enhancements in tumour oxygenation could be especially
important when combining antiangiogenic agents with conven-
tional therapies, such as radiotherapy and chemotherapy, each
of which directly depends on microregional tumour blood
flow and oxygenation. The current work utilised MCF-7 breast
cancer cells transfected with either VEGF121 or VEGF165.
In addition, since FGF-1 has been similarly associated
with highly vascularised tumours (Zhang et al, 1997), FGF-1-
overexpressing transfectants were included for comparison.
Using a combination of immunohistochemistry and image analysis
techniques, four pathophysiological indices were determined: (1)
total vessel spacing, (2) perfused vessel spacing, (3) % vascular
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yarea, and (4) overall tumour hypoxia. Results demonstrate that
among these angiogenic growth factors, only VEGF121 over-
expression produced significant alterations in overall tumour
oxygenation.
MATERIALS AND METHODS
Cell lines and reagents
MCF-7 cells were obtained from American Tissue Culture
Collection (ATCC, Rockville, MD, USA), and MCF-7 cells that
stably express VEGF or FGF-1 were generated by transfecting
MCF-7 cells with VEGF121, VEGF165, or FGF-1 cDNA. The clones
that highly expressed exogenous VEGF121, VEGF165, or FGF-1 were
expanded and characterised by methods described previously
(Zhang et al, 1997; Guo et al, 2001; Guo et al, 2003). We detected
similar levels of VEGF protein in the total cell lysates of both
VEGF121- and VEGF165-expressing cells by Western blotting using
an anti-VEGF antibody. In a 48h cell culture, VEGF121-expressing
cells secreted 296.6ng VEGFml
 110
6 cells
 1 and VEGF165-expres-
sing cells produced 382.3ng VEGFml
 110
6 cells
 1 into the
conditioned media, as determined by VEGF ELISA assays. We
also obtained three additional VEGF-expressing cell clones in each
class that express VEGF at similar levels (Guo et al, 2003). Human
MCF-7 breast tumours were grown in the mammary fat pads of
ovariectomised female nude mice as described previously (Guo
et al, 2001). Briefly, 1 10
7 cells were inoculated into the
mammary fat pads of 7–8-week old, ovariectomised female nude
mice that were implanted with 17-b estradiol 60-day slow release
pellets (Innovative Research of America, Sarasota, FL, USA). The
volumes of the tumours were measured using calipers and the
formula 1
2ab2 (where a and b are the major and minor tumour
dimensions).
DiOC7 perfusion marker and EF5 hypoxic marker
To visualise blood vessels open to flow, an intravascular stain,
DiOC7, was injected 1min prior to freezing to preferentially stain
cells adjacent to the vessels (Fenton et al, 1999). Localised areas of
tumour hypoxia were assessed in frozen tissue sections by
immunohistochemical identification of sites of 2-nitroimidazole
metabolism (EF5 binding) (Fenton et al, 1999). EF5 (from NCI)
was injected i.v. 1h before tumour freezing, at which time the EF5
is well distributed throughout even poorly perfused regions of the
tumour (Fenton et al, 2001). Regions of high EF5 metabolism were
visualised immunohistochemically using a Cy3 fluorochrome
conjugated to the ELK3-51 antibody, which is extremely specific
for the EF5 drug adducts that form when the drug is incorporated
by hypoxic cells (Lord et al, 1993).
Immunohistochemistry and image analysis
Tumour sections were imaged using a  20 objective, digitised
(Sony DXC9000 3CCD camera), background-corrected, and image-
analysed using Image-Pro software (Media Cybernetics, Silver
Spring, MD, USA) (Fenton et al, 1999). Colour image montages
from 16 adjacent microscope fields in each of four tumour regions
(encompassing roughly 15mm
2) were automatically acquired and
digitally combined under three different staining conditions. First,
images of the DiOC7 were obtained immediately after the frozen
sections were sliced on the cryostat. Following staining, the section
was returned to the same stage coordinates, and imaged for both
hypoxia (EF5) and total vasculature (antipanendothelial cell
antigen, Pharmingen, San Diego, CA, USA). The total vasculature
and perfused vasculature images were enhanced using colour
segmentation to identify appropriate blood vessels (Fenton et al,
1999). Using ‘distance map’ filtering of the segmented images,
individual pixel intensities were converted to levels directly
proportional to the distances between tumour cells and the nearest
blood vessel (Fenton et al, 2002). Percentage vascular area (defined
as total or perfused vessel area/total tissue area) was also
determined using Image Pro software. Finally, fluorescent image
montages of the EF5/Cy3 staining were quantified by determining
the mean pixel intensity of each image (range: 0–255). CCD
camera settings were set to a constant shutter speed of 1/60, with
constant gain, contrast, and brightness settings.
Statistical analysis
Tumour means were compared using the Student’s t-test and
differences were considered significant for Po0.05.
RESULTS
Overexpression of VEGF121, VEGF165, or FGF-1 by MCF-7
cells enhanced oestrogen-dependent tumour growth
To determine whether expression of VEGF121, VEGF165, or FGF-1
by MCF-7 cells enhances MCF-7 breast tumour growth in vivo,
MCF-7 vector controls, VEGF121, VEGF165, or FGF-1 cells were
implanted orthotopically. At 45 days postimplantation, 40% of
mice that received MCF-7/vector cells developed tumours, and
volumes averaged 242750.6mm
3. In contrast, expression of
VEGF121, VEGF165, or FGF-1 not only increased the frequency of
MCF-7 tumour formation but also dramatically enhanced tumour
growth. As summarised in Table 1, tumour volumes were
significantly increased for each of the three transfectants in
relation to vector controls (Po0.001).
VEGF121, VEGF165, and FGF-1 have varying effects on
tumour vascularity and perfusion
Since tumour vascularity and hypoxia have been shown to
vary with tumour volume (Fenton et al, 1988), a separate set of
volume-matched tumours was used for the pathophysiological
measurements. The mean volumes7s.e. were as follows: vectors
(410790mm
3), VEGF121 (440730), VEGF165 (570780), and
FGF-1 (440790). Compared to vector controls, total vessel spacing
was significantly decreased in both the VEGF121 (Po0.001)
and VEGF165 (P¼0.001) tumours, but unchanged in the FGF-1
tumours (see Figures 1A–D and 2A). Note that this decrease in
vascular spacing corresponds to the increased vascularity shown
in Figure 1. Perfused vessel spacing (Figure 2B), on the other hand,
was significantly decreased for both the VEGF121 (Po0.001)
and FGF-1 (Po0.013) tumours, but not for the VEGF165 (P¼0.15)
(see Figures 1E–H for representative images of the green perfusion
stain superimposed on the orange hypoxia stain). To determine
whether vascularity or perfusion varied with depth into
the tumour, additional low-power image montages ( 10 objec-
tive) were also acquired to contrast vascular spacing in the
centre (defined by a circular region of diameter 3000mm) vs the
periphery of the tumour cross-section. On average, neither total
nor perfused vessel spacing varied significantly with depth into the
Table 1 Tumour formation percentage and tumour volume at 45 days
postimplantation
Frequency (%) Tumour formation
Tumour volume (mm
3)
Mean7s.e.
Vector 40 240750
VEGF121 90 12607210
VEGF165 86 16407190
FGF-1 74 7607120
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shown). However, two distinctly different vascular patterns were
observed among VEGF165 tumours. In roughly half of these
tumours, a central region of hypoxia developed that was
surrounded by a densely vascularised peripheral rim of vessels
(Figure 1I), but in the others, vessels were fairly evenly distributed
(Figure 1J).
Vessel diameters and interconnectivity ( 20 objective)
were also markedly different among the transfectants, as
shown in Figures 1A–D. In comparison to vector controls,
percentage areas of both total (open bars in Figure 2C) and
perfused (filled bars in Figure 2C) vessels were significantly
increased for each of the three transfectants, again most strikingly
for the VEGF121 tumours.
VEGF121 overexpression reduces overall tumour hypoxia
Overall tumour hypoxia was characterised by measuring the mean
intensity of the Cy3 conjugated antibody to the EF5 hypoxia
marker. As summarised in Figure 2D (and shown by the orange
staining in Figures 1E–H), overall tumour hypoxia was unchanged
in the VEGF165 and FGF-1 tumous, but significantly reduced in the
VEGF121 tumours (P¼0.026) compared to vector controls. This
decrease in hypoxia for the VEGF121 tumours is in agreement with
the striking decrease in perfused vessel spacing observed for these
tumours (Figure 2B), which corresponds to a decrease in the
distance oxygen must diffuse to reach the tumour cells most
distant from the vessels. In the case of the FGF-1 tumours,
however, overall tumour hypoxia was unchanged despite a
Figure 1 Representative immunohistochemical staining of antipanendothelial cell antigen in panels (A–D), with corresponding images of the DiOC7
perfusion marker (green) superimposed over the EF5 hypoxia marker (orange), in panels (E–J). Intensely stained orange regions of (E–J) correspond to
increased tumour hypoxia. MCF-7 vector is shown in (A) and (E), VEGF121 in (B) and (F), VEGF165 in (C) and (G), and FGF-1 in (D) and (H). Each of
panels (A–H) are portions of the original 4 4 composite images taken with a  20 objective, and the bar in panel (E) equals 100mm. Panels (I) and (J)
are entire 4 4 composites taken with a  10 objective (bar in panel (I) equals 500mm), illustrating the two general patterns of vascular configuration and
hypoxia observed in VEGF165 tumours. Peripheral vasculature with centralised hypoxia is shown in panel (I), and a more randomly distributed pattern of
vasculature and hypoxia is shown in panel (J).
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tumours) decrease in perfused vessel spacing.
DISCUSSION
While VEGF is well accepted as an important modulator of tumour
growth and vascular development, specific pathophysiological
alterations associated with the different VEGF isoforms are
less well understood. The current work reaffirms the notion
that different VEGF isoforms lead to distinct differences in tumour
vascular structure when compared at the same implantation
site. In addition, we found that such vascular changes are, in
some cases, directly associated with alterations in tumour
oxygenation.
In previous studies, results have varied widely in terms of both
tumour growth rate and vascular density when different tumour
models and implantation sites were considered. Guo et al (2001)
demonstrated that microenvironmental factors may be important,
comparing VEGF121- and VEGF165-transfected glioma cell lines
implanted either subcutaneously (s.c.) or intracranially (i.c.).
VEGF165 transfectants grew much more rapidly than wild type
at either location, with a corresponding increase in vascular
density at both. Interestingly, VEGF121 transfectants exhibited
enhanced vessel growth only when implanted orthotopically in
the brain.
Using transfected fibrosarcoma cell lines, Grunstein et al (2000)
proposed a model in which the different VEGF isoforms
preferentially recruit blood vessels to either the tumour interior
or periphery. It was suggested that these vascular patterns could
possibly relate to the diffusibility of the VEGF121 vs the VEGF165.I n
this model, VEGF120-overexpressing tumours tended to more
effectively recruit systemic vessels, but failed to develop adequate
internal vascularisation (Grunstein et al, 2000), while VEGF164
tumours were capable of inducing both external and internal
vascular expansion. In human melanoma transfectants, overall
growth rate of the tumours correlated only with the amount of
secretable VEGF, rather than on which specific VEGF isoform was
overexpressed (Yu et al, 2002). Although VEGF121 tumours were
more densely vascularised at the tumour periphery (with more
central necrosis), VEGF165 tumours produced a much more
densely vascularised plexus of blood vessels overall.
In the current study, human MCF-7 cells were implanted
orthotopically in the mammary fat pad. Growth rates of VEGF121
and VEGF165 transfectants were significantly higher than vector
controls and essentially equal to each other, while FGF-1 tumours
grew at a somewhat less rapid rate. Both VEGF121 and VEGF165
produced densely arcading networks of blood vessels of increased
vascular diameter. In contrast to both the fibrosarcomas and
melanomas, however, spatial heterogeneities in vascular spacing
were generally not observed. On average, neither total nor perfused
vascular spacing varied as a function of distance from the tumour
Figure 2 Effects of VEGF isoforms and FGF-1 on vascular spacing, % vascular area, and overall hypoxia. Data are presented as median distances
(mean7s.e.) to the nearest total (A) or perfused (B) blood vessel, and increased median distances correspond to decreased vascular densities. An
increased disparity between the total and perfused bars for a given tumour type indicates an increased proportion of nonfunctional vessels in that tumour.
Data are averaged over four 4 4 image montages (64 fields) from each of 10 MCF-7 vectors (mean volume7s.e.m.¼410790mm
3), six VEGF121
tumours (440730)), five VEGF165 tumours (570780), and nine FGF-1 tumours (440790). (C) Percentage vascular area for total (open bars) and perfused
(filled bars) vessels. Asterisks denote statistically significant differences from vector controls. (D) Tumour hypoxia, as measured by overall EF5/Cy3 intensity
(mean7s.e.), again averaged over four 4 4 image montages.
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of the VEGF165 tumours demonstrated a reduction in vasculature
in the tumour centre compared to periphery. Also, in contrast to
previous reports in other models, MCF-7 VEGF121 transfectants
were much more evenly vascularised than the VEGF165,a s
measured by the reduction in vascular spacing. Although the
reasons for these disparate findings are unclear, spatially
dependent vascular heterogeneities could possibly be related to
either specific implantation site or differences in tumour volume.
A key advantage in our method of measuring vascular spacing,
rather than the more commonly reported ‘vesselsfield
 1’o r
‘positive pixelsmm
 2’, is that vascular spacing is more closely
related to the ability of the blood vessels to uniformly supply the
tumour with oxygen and nutrients. Especially in tumours contain-
ing an uneven distribution of vessels, determinations of mean
vascular density can be highly misleading in terms of tumour
oxygen delivery. For example, a tumour with a highly localised
cluster of dense vascularisation could have an overall vascular
density equal to that of a tumour having a reduced but
homogeneous distribution of vessels. Clearly, microregional
efficiencies in the delivery of either oxygen or chemotherapeutic
agents would be quite different between the two. Such differences
are apparent when using our ‘distance map’ measurements of
vascular spacing, which depend on vessel number, size, and spatial
distribution. Although neither perfused vessel spacing nor tumour
hypoxia was significantly altered in the VEGF165 tumours, VEGF121
tumours demonstrated significant changes in both. This decrease
in perfused vessel spacing suggests that these vessels are more
efficiently distributed in the VEGF121 tumours, which is supported
by the significant decrease in overall tumour hypoxia observed in
these tumours.
Finally, FGF-1 transfectants have also been reported to form
large, vascularised tumours and to confer a more malignant
phenotype upon MCF-7 cells, without oestrogen supplementation
(Zhang et al, 1997). In the current studies, FGF-1 overexpression
led to a substantial increase in tumour growth rate, with a
significant decrease in the perfused vessel spacing. Conceivably,
this increase in perfused vasculature could translate to an
increased opportunity for these tumour cells to invade into the
circulation and metastasise (Zhang et al, 1997).
A major unanswered question raised by this and previous
studies is why VEGF121 and VEGF165 isoforms have such disparate
effects on vascular structure and function among different tumour
models. Although tumorigenicity and vascular growth were
increased by both in all of the previously cited tumour models,
specific alterations in vascular morphology were distinctly
different. Interestingly, it has been reported that while VEGF121
is the predominant form expressed in human breast carcinomas
(Relf et al, 1997) and melanomas (Yu et al, 2002), the VEGF165
variant is predominant in glioblastomas (Berkman et al, 1993).
This is intriguing in view of the fact that the vascular modification
associated with VEGF121 or VEGF165 transfectants of the three
tumour types do not necessarily follow this same pattern. In breast
tumours, the predominant variant, VEGF121, was also the
more effective in inducing extensive tumour vascularisation
when overexpressed in that model. In melanomas and gliomas,
however, an entirely different relationship holds true, and in
each case, the predominant isoform is the less important in terms
of promoting vascular development (Guo et al, 2001; Yu et al,
2002).
Previous studies have speculated that differences in vascular
configuration between VEGF121 and VEGF165 may be related to
variations in heparin binding, isoform size, or diffusivity (Guo
et al, 2001; Yu et al, 2002). It has also been hypothesised that
variations in isoform expression may confer differential advan-
tages on tumours as they expand in the different sites, each of
which may possess different requirements for neovascularisation
(Grunstein et al, 2000). Further detailed studies are needed to
determine whether vascular response is primarily dictated by the
immediate microenvironment of the tumour, including proximity
to nearby pre-existing host vessels, or instead related to local
balances among additional angiogenic growth factors and in-
hibitors.
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